

PERSONAL INFORMATION

Momir Radulović

Living in 6 and working in 10 different countries with diverse Health systems and cultural environments, different work areas, projects, and assignments, gives me experience to adapt quickly to changes in environment with positive reframe attitude. I am curious cultural shock absorber with passion for innovation & "connecting the dots". I have track record of strong results, enjoy prioritizing, simplifying complex ideas and acting on them with high levels of energy.

WORK EXPERIENCE

December 2018 - present

Executive DirectorAgency for Medicinal Products and Medical Devices of the Republic of Slovenia www.jazmp.si

- Strategic planning and management ~ € 8m
- Number of Staff overseen ~ 150
- Successful Agency's Crisis management and recovery after financial setback in 2017, 2018 Increased Income activities, achieved financial stability and sustainability
- Implementation of EU Pharma Strategy with 2021 SI Presidency proposal to build resilient European Health Union with joint solutions (non-for-profit production) for medicines with low commercial interest, e.g. antibiotics and drug repurposing
- Regulation of human and veterinary medicines, SI as Rapp or CoRapp in EMA centralized procedures and MNATs, and as RMS in MRP/DCP
- Inspectorate for GMP, GCP, GDP and Pharmacies
- Medical devices regulation and surveillance
- National Pharmacovigilance, Histovigilance and Hemovigilance centre
- Regulation and inspectorate of blood and blood products, human tissues, and cells
- Designation and supervision of Notified body for medical devices (SIQ)
- Regulation and control homeopathic and natural-origin medicinal products, active substances, illicit drugs groups II and III
- Regulation of List prices of Medicinal Products
- National Pharmacopoeia Authority, ...

December 2018 - present

EMA Management Board Member<https://www.ema.europa.eu/en/about-us/who-we-are/management-board/members>

June 2021 - present

Heads of Medicines Management Group Memberwww.hma.eu

June 2022 - present

EURIPID Chair of the Board of ParticipantsEuropean Integrated Price Information Database <https://euripid.eu/organisation/>

May 2018 – Nov 2018

Business Unit Head Vaccines and HIV

GSK, Slovenia

Jun 2017 – Apr 2018

Sabbatical year – taking time off, time is our most valuable asset

Everywhere

Apr 2016 – Jun 2017

Market Access and Health Policy Lead Central Asia, Caucasus, and Mongolia

Roche, 8 countries

Jan 2015 – Mar 2016

Business Unit Head Oncology & Haematology; Deputy General Manager

Roche Kazakhstan

Dec 2005 – Dec 2014

Various Roles in Marketing, Sales and e-marketing in Roche

Roche Slovenia, Roche Poland, Roche Russia, Roche Adriatic

EDUCATION AND TRAINING

Oct 1998 – Oct 2005

Master of Pharmacy; Certified Pharmacist

Faculty of Pharmacy, University of Ljubljana; Ministry of Health / Slovene Chamber of Pharmacies

ADDITIONAL INFORMATION

Memberships

- European Clinical Research Alliance on Infectious Diseases (**ECRAID**) **Supervisory Board member**; www.ecraid.eu
- European Commission **Pharmaceutical Committee member**, https://health.ec.europa.eu/medicinal-products/pharmaceutical-committee-veterinary-pharmaceutical-committee-and-expert-groups/human-pharmaceutical-committee-meetings_en
- EATRIS **REMEDI4ALL consortium Policy Board member**
European innovation platform to enhance repurposing of medicines for all, <https://eatris.eu/projects/remedi4all-building-a-sustainable-european-innovation-platform-to-enhance-the-repurposing-of-medicines-for-all/>
- Critical Path Institute (C-Path), CURE Drug Repurposing Collaboratory, **Regulatory Policy and Legislative Group member**, <https://c-path.org/programs/cdrc/>
- MoH **Community Pharmacy Extended Expert Group member**, <https://www.gov.si/zbirke/delovna-tesesa/rsk-za-lekamisko-farmacijo/>
- Executive Steering Group on Shortages and Safety of Medicinal Products (**MSSG**) **member**
- EU Network Training centre (**EU NTC**) **member**, <https://www.hma.eu/about-hma/working-groups/eu-network-training-centre-eu-ntc-former-otsg.html>
- Accelerating Clinical Trials in the EU (**ACT EU**) **PA4 Co-Lead**
<https://www.ema.europa.eu/en/news/accelerating-clinical-trials-eu-act-eu-better-clinical-trials-address-patients-needs>
- HMA Working group of Biosimilars (**BSWG**) **member**, <https://www.hma.eu/about-hma/working-groups/hma-working-group-of-biosimilars.html>
- Oslo Medicines Initiative (**OMI**) **Program Scientific Board Member**, <https://www.omi-euro.org/>